<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193372</url>
  </required_header>
  <id_info>
    <org_study_id>19638</org_study_id>
    <nct_id>NCT03193372</nct_id>
  </id_info>
  <brief_title>A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea</brief_title>
  <official_title>A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To survey rosacea patients about their concerns, treatment satisfaction, and quality of life
      associated with their Finacea Foam treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2017</start_date>
  <completion_date type="Actual">November 15, 2017</completion_date>
  <primary_completion_date type="Actual">August 8, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Demographics and clinical characteristics</measure>
    <time_frame>one-time survey in 2 week recruitment window</time_frame>
    <description>Collected patient demographics and characteristics are :
Year of birth
Gender
Insurance type</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rosacea-relevant comorbidities and complications</measure>
    <time_frame>one-time survey in 2 week recruitment window</time_frame>
    <description>Patient reported history of the following will be collected :
Blepharitis
Conjunctivitis
Corneal neovascularization/keratitis
Depression
Migraine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rosacea subtype</measure>
    <time_frame>one-time survey in 2 week recruitment window</time_frame>
    <description>Patient reported diagnosis of the following will be collected:
Erythematotelangiectatic (facial redness)
Papulopustular (bumps and pimples)
Phymatous (enlargement of the nose)
Ocular (eye irritation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Past use of topical rosacea treatments</measure>
    <time_frame>one-time survey in 2 week recruitment window</time_frame>
    <description>Patient reported use of the following medications will be collected:
Metronidazole gel
Metronidazole cream
Metronidazole lotion
Metronidazole emulsion
Brimonidine tartrate gel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient concerns collected by Rosacea Treatment Preference Questionnaire</measure>
    <time_frame>one-time survey in 2 week recruitment window</time_frame>
    <description>Rosacea Treatment Preference Questionnaire is a survey to assess patient self-reported rosacea subtype and severity, and to evaluate the concerns that contribute to patient satisfaction/dissatisfaction, as well as treatment decisions with rosacea topical treatments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment satisfaction assessed by Satisfaction with Medicines Questionnaire (SATMED-Q)</measure>
    <time_frame>one-time survey in 2 week recruitment window</time_frame>
    <description>SATMED-Q is a 17-question, validated, multidimensional generic questionnaire designed for use in patients with any chronic disease treated with medicines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life measured by Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>one-time survey in 2 week recruitment window</time_frame>
    <description>DLQI is a widely used dermatology-related quality of life tool</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2200</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Rosacea Concierge Program</arm_group_label>
    <description>Patients diagnosed with rosacea and currently receiving topical monotherapy with Finacea Foam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finacea Foam, (Azelaic Acid, BAY39-6251)</intervention_name>
    <description>Finacea Foam, Active substance Azelaic acid</description>
    <arm_group_label>Rosacea Concierge Program</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with rosacea and currently receiving topical monotherapy with Finacea
        Foam
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Diagnosis of rosacea by a medical professional

          -  Currently using Finacea Foam as topical monotherapy for rosacea

          -  Willing and able to provide voluntary, informed consent to participate in this study

        Exclusion Criteria:

        - Use of any other topical treatment for rosacea at the time of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xcenda, LLC</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34685</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azelaic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

